Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐267
Biopharmaceutics & Drug Disposition · 2024
DOI: 10.1002/bdd.2381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, 2024. Verfasst von Cui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henan Province Hospital of Chinese Medicine, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzho…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Diabetes Mellitus, Type 2, Piperidines, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
SCO‐267 is a potent G‐protein‐coupled receptor 40 agonist that is undergoing clinical development for the treatment of type 2 diabetes mellitus. The current work was undertaken to investigate the bioactivation potential of SCO‐267 in vitro and in vivo . Three SCO‐267‐derived glutathione (GSH) conjugates (M1–M3) were found both in rat and human liver microsomal incubations supplemented with GSH and nicotinamide adenine dinucleotide phosphate. Two GSH conjugates (M1–M2) together with two N‐ acetyl‐cysteine conjugates (M4–M5) were detected in the bile of rats receiving SCO‐267 at 10 mg/kg. The identified conjugates suggested the generation of quinone‐imine and ortho ‐quinone intermediates. CYP3A4 was demonstrated to primarily catalyze the bioactivation of SCO‐267. In addition, SCO‐267 concentration‐, time‐, and NADPH‐dependently inactivated CYP3A in human liver microsomes using testosterone as a probe substrate, along with K I and k inact values of 4.91 μM and 0.036 min −1 , respectively. Ketoconazole (a competitive inhibitor of CYP3A) displayed no significant protective effect on SCO‐267‐induced CYP3A inactivation. However, inclusion of GSH showed significant protection. These findings revealed that SCO‐267 undergoes a facile CYP3A4‐catalyzed bioactivation with the generation of quinone‐imine and ortho ‐quinone intermediates, which were assumed to be involved in SCO‐267 induced CYP3A inactivation. These findings provide further insight into the bioactivation pathways involved in the generation of reactive, potentially toxic metabolites of SCO‐267. Further studies are needed to evaluate the influence of SCO‐267 metabolism on the safety of this drug in vivo .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Henan Province Hospital of Chinese Medicine, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.
- Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.
- TriApex Laboratories Co. Ltd, Nanjing, China.
ORCID-Profile: Xu Zhao
Zitieren
APA
Li, C., Li, X., Fan, A., He, N., Wu, D., Yu, H., Wang, K., Jiao, W., & Zhao, X. (2024). Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐267. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2381
Vancouver
Li C, Li X, Fan A, He N, Wu D, Yu H, et al. Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐267. Biopharmaceutics & Drug Disposition. 2024. doi:10.1002/bdd.2381
BibTeX
@article{Li2024,
author = {Li, Cui and Li, Xiaokun and Fan, Ali and He, Ning and Wu, Dongmei and Yu, Hongyan and Wang, Kun and Jiao, Weijie and Zhao, Xu},
title = {Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐267},
journal = {Biopharmaceutics & Drug Disposition},
year = {2024},
doi = {10.1002/bdd.2381}
}
EUVIMED